S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:OCUL

Ocular Therapeutix News Headlines

$18.51
+1.18 (+6.81 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.16
Now: $18.51
$18.56
50-Day Range
$17.33
MA: $19.19
$21.44
52-Week Range
$3.78
Now: $18.51
$24.30
Volume1.30 million shs
Average Volume938,285 shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.29

Headlines

Ocular Therapeutix (NASDAQ OCUL) News Headlines Today

Source:
SourceHeadline
Financial Analysis: Amicus Therapeutics (NASDAQ:FOLD) and Ocular Therapeutix (NASDAQ:OCUL)Financial Analysis: Amicus Therapeutics (NASDAQ:FOLD) and Ocular Therapeutix (NASDAQ:OCUL)
americanbankingnews.com - March 6 at 2:10 PM
Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching ...Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching ...
businesswire.com - March 4 at 7:46 PM
Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should KnowWill Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know
finance.yahoo.com - March 4 at 7:46 PM
Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic ConjunctivitisOcular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
finance.yahoo.com - March 4 at 7:46 PM
Ocular Therapeutix (OCUL) Scheduled to Post Earnings on ThursdayOcular Therapeutix (OCUL) Scheduled to Post Earnings on Thursday
americanbankingnews.com - March 4 at 1:34 AM
Ocular Therapeutix (NASDAQ:OCUL)  Shares Down 7.1% Ocular Therapeutix (NASDAQ:OCUL) Shares Down 7.1%
americanbankingnews.com - March 3 at 8:06 PM
Ocular Therapeutix (NASDAQ:OCUL) Trading 6.1% Higher Ocular Therapeutix (NASDAQ:OCUL) Trading 6.1% Higher
americanbankingnews.com - March 1 at 9:00 PM
Ocular Therapeutix™ Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye DiseaseOcular Therapeutix™ Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
finance.yahoo.com - March 1 at 8:47 AM
Ocular Therapeutix™ To Report Fourth Quarter and Year End 2020 Financial ResultsOcular Therapeutix™ To Report Fourth Quarter and Year End 2020 Financial Results
finance.yahoo.com - February 25 at 12:57 PM
Global $60+ Billion Ophthalmic Drugs Market to 2028: Patent Expiry Of Blockbuster Drugs to Limit Market growthGlobal $60+ Billion Ophthalmic Drugs Market to 2028: Patent Expiry Of Blockbuster Drugs to Limit Market growth
finance.yahoo.com - February 24 at 8:38 PM
Ocular Therapeutix™ to Participate at Three Upcoming Investor ConferencesOcular Therapeutix™ to Participate at Three Upcoming Investor Conferences
finance.yahoo.com - February 24 at 9:49 AM
Global Hydrogel Market Size 2021 Top Manufacturers, Share, Growth Factor, Latest Trends, Type and Application Forecast 2026Global Hydrogel Market Size 2021 Top Manufacturers, Share, Growth Factor, Latest Trends, Type and Application Forecast 2026
marketwatch.com - February 23 at 8:11 AM
Ocular Therapeutixs (NASDAQ:OCUL) Wonderful 301% Share Price Increase Shows How Capitalism Can Build WealthOcular Therapeutix's (NASDAQ:OCUL) Wonderful 301% Share Price Increase Shows How Capitalism Can Build Wealth
finance.yahoo.com - February 19 at 3:13 PM
Ocular Therapeutix (NASDAQ:OCUL) Trading Up 6.6%Ocular Therapeutix (NASDAQ:OCUL) Trading Up 6.6%
americanbankingnews.com - February 18 at 7:06 PM
3 Top Healthcare Stocks to Buy Now3 Top Healthcare Stocks to Buy Now
finance.yahoo.com - February 17 at 10:07 AM
3 Reasons to Buy Ocular Therapeutix Stock Right Now3 Reasons to Buy Ocular Therapeutix Stock Right Now
finance.yahoo.com - February 16 at 7:26 AM
Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2021 – Virtual EditionOcular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition
finance.yahoo.com - February 12 at 8:12 AM
Ocular Drug Delivery Mode Market Size Detailed Analysis of Current Industry Figures with Forecasts Growth By 2025Ocular Drug Delivery Mode Market Size Detailed Analysis of Current Industry Figures with Forecasts Growth By 2025
marketwatch.com - February 11 at 5:00 PM
Ocular Therapeutix™ Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10 th ...Ocular Therapeutix™ Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10 th ...
businesswire.com - January 20 at 12:45 PM
Ocular Therapeutix™ Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10th Annual Glaucoma 360 New Horizons ForumOcular Therapeutix™ Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10th Annual Glaucoma 360 New Horizons Forum
finance.yahoo.com - January 20 at 12:45 PM
Global Sustained Release Ocular Drug Delivery Systems Market Driving Factors, 2026 Market Analysis, Investment Feasibility and TrendsGlobal Sustained Release Ocular Drug Delivery Systems Market Driving Factors, 2026 Market Analysis, Investment Feasibility and Trends
marketwatch.com - January 15 at 1:16 PM
Ocular Therapeutix™ Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD asOcular Therapeutix™ Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as
bloomberg.com - January 7 at 8:54 AM
Ocular Therapeutix™ Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical DevelopmentOcular Therapeutix™ Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical Development
finance.yahoo.com - January 7 at 8:54 AM
Clearside Biomedical: SCS Microinjector Platform With Significant UpsideClearside Biomedical: SCS Microinjector Platform With Significant Upside
seekingalpha.com - January 6 at 5:53 PM
Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock OptionsImplied Volatility Surging for Ocular Therapeutix (OCUL) Stock Options
finance.yahoo.com - January 6 at 12:52 PM
Ocular TherapeutixTM Announces Exercise of Underwriters Option to Purchase Additional SharesOcular TherapeutixTM Announces Exercise of Underwriters' Option to Purchase Additional Shares
benzinga.com - December 29 at 11:00 PM
Ocular TherapeutixTM Announces Exercise of Underwriters’ Option to Purchase Additional SharesOcular TherapeutixTM Announces Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - December 28 at 9:06 AM
Oculars (OCUL) sNDA for Dextenza Gets FDA Acceptance, Shares UpOcular's (OCUL) sNDA for Dextenza Gets FDA Acceptance, Shares Up
finance.yahoo.com - December 23 at 5:22 PM
Ocular Therapeutix™ Announces Submission to the FDA of a Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic ConjunctivitisOcular Therapeutix™ Announces Submission to the FDA of a Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
finance.yahoo.com - December 22 at 10:22 AM
Heres What We Learned About The CEO Pay At Ocular Therapeutix, Inc. (NASDAQ:OCUL)Here's What We Learned About The CEO Pay At Ocular Therapeutix, Inc. (NASDAQ:OCUL)
finance.yahoo.com - December 21 at 12:38 PM
Ocular TherapeutixTM Announces Pricing of Public Offering of Common StockOcular TherapeutixTM Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - December 16 at 1:32 AM
Is OCUL A Good Stock To Buy Now?Is OCUL A Good Stock To Buy Now?
finance.yahoo.com - December 12 at 3:48 AM
Ocular Therapeutix™ to Present at the Piper Sandler 32nd Annual Virtual Healthcare ConferenceOcular Therapeutix™ to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
finance.yahoo.com - November 23 at 10:33 AM
Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual MeetingOcular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting
finance.yahoo.com - November 11 at 9:14 AM
Ocular Therapeutix™ to Participate at Two Upcoming Investor ConferencesOcular Therapeutix™ to Participate at Two Upcoming Investor Conferences
finance.yahoo.com - November 9 at 7:26 PM
Ocular Therapeutix Rises 7% On Stellar Results Backed By DextenzaOcular Therapeutix Rises 7% On Stellar Results Backed By Dextenza
finance.yahoo.com - November 9 at 2:26 PM
Ocular Therapeutix +9.2% Q3 smasher, revenue surges on drug used for ocular inflammation and painOcular Therapeutix +9.2% Q3 smasher, revenue surges on drug used for ocular inflammation and pain
seekingalpha.com - November 6 at 6:43 PM
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates (Revised)Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates (Revised)
finance.yahoo.com - November 6 at 3:42 AM
Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q3 2020 Results - Earnings Call TranscriptOcular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 5 at 10:13 PM
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue EstimatesOcular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 5 at 10:13 PM
Ocular Therapeutix™ Reports Third Quarter 2020 Financial Results and Business UpdateOcular Therapeutix™ Reports Third Quarter 2020 Financial Results and Business Update
finance.yahoo.com - November 5 at 5:12 PM
Industry Analysts Just Upgraded Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Revenue Forecasts By 13%Industry Analysts Just Upgraded Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Revenue Forecasts By 13%
nasdaq.com - November 4 at 8:32 PM
Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code from the American Medical Association for the Insertion of Intracanalicular InsertsOcular Therapeutix Announces Receipt of a Permanent Category I CPT Code from the American Medical Association for the Insertion of Intracanalicular Inserts
finance.yahoo.com - November 4 at 10:31 AM
Ocular Therapeutix IncOcular Therapeutix Inc
bloomberg.com - October 30 at 10:00 AM
Ocular Therapeutix inks distribution deal in Asia valued up to $103MOcular Therapeutix inks distribution deal in Asia valued up to $103M
seekingalpha.com - October 30 at 10:00 AM
Ocular Therapeutix (OCUL) May Report Negative Earnings: Know the Trend Ahead of Next Weeks ReleaseOcular Therapeutix (OCUL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
finance.yahoo.com - October 29 at 6:13 PM
Ocular Therapeutix™ To Report Third Quarter 2020 Financial ResultsOcular Therapeutix™ To Report Third Quarter 2020 Financial Results
finance.yahoo.com - October 23 at 11:16 AM
Ocular Therapeutixs (OCUL) Shares March Higher, Can It Continue?Ocular Therapeutix's (OCUL) Shares March Higher, Can It Continue?
nasdaq.com - October 22 at 12:41 PM
Ocular Therapeutix's (OCUL) Shares March Higher, Can It Continue?Ocular Therapeutix's (OCUL) Shares March Higher, Can It Continue?
finance.yahoo.com - October 22 at 12:41 PM
Ocular Therapeutix reaches agreement with FDA to conduct retrospective study for ReSure sealantOcular Therapeutix reaches agreement with FDA to conduct retrospective study for ReSure sealant
seekingalpha.com - October 15 at 8:35 AM
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.